Meeting
2019 ASCO Annual Meeting
Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.
Authors
Vaia Florou
University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL
Vaia Florou , Wungki Park , Peter Joel Hosein , Breelyn A. Wilky , Jonathan C. Trent , Gilberto Lopes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2617)
DOI
10.1200/JCO.2019.37.15_suppl.2617
Abstract #
2617
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).
First Author: Mariona Riudavets
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2023 ASCO Annual Meeting
Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.
First Author: Thierry Landre